

## Working Groups

# Recommendations for coding Bladder Tumours

Distributed in 1995

All bladder tumours should be registered, whatever the histological type and level of invasion.

## Principles

The coding of tumour behaviour (/1, /2, /3) takes into account both the anatomopathological definition and the extent of invasion. It is, therefore, essential to have access to reports of any pathological examinations.

## Rules

### Tumour behaviour code: /1

Normal or slightly abnormal histology: low grade papillary urothelial tumours, not invasive.

In the various anatomopathological classifications these tumours are called:

- . benign or simple papillomas,
- . papillary urothelial tumours,
- . stage I carcinoma (BRODERS' classification),
- . well-differentiated papillary carcinoma (JEWETT's classification),
- . grade I carcinoma (in the WHO classification), or
- . classes I and IIs (CHOME's classification).

Extent of invasion - none.

### Tumour behaviour code: /2

Presence of mitoses and more markedly atypical cells than in the previous categories. It includes both high grade papillary urothelial tumours and flat tumours.

Extent of invasion - none.

### Tumour behaviour code: /3

Invasion present, whatever the anatomopathological definition.

### Particular cases:

- Carcinoma in situ: /2

The particular entity which consists of carcinoma in situ displaying clear anaplasia of the superficial epithelium without the formation of a papillary structure and without invasion is coded to 8010/2.

- Anatomopathological examination indicates the existence of a tumour, but it is not possible to determine the degree of malignancy on the specimen examined:

Code: /1 tumour benign or of uncertain malignancy

- Anatomopathological proof unavailable, but the clinical appearance is confirmed by the clinician:

8000/0: No microscopical confirmation:  
tumour clinically benign.

8000/1: No microscopical confirmation:  
tumour clinically of uncertain behaviour.

8000/3: No microscopical confirmation:  
tumour clinically malignant.

---

**Working Group Members:**

Dr Derek Pheby (Chairman), University of West of England, Bristol, UK

Dr Carmen Martínez, Granada Cancer Registry, Granada, Spain

Dr Martine Roumagnac, Tarn Cancer Registry, Albi, France

Dr Leo Schouten, Maastricht Cancer Registry, Maastricht, The Netherlands

---